Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Conditions

• Blunt Cerebrovascular Injury

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Aspirin 325Mg Tab, Aspirin 81Mg Tab — DRUG
  Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.

Study Details

The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.

Key Dates

Start date

Aug 23, 2023

Status verified

Jan 2026

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

98 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Active Comparator: Oral Daily Aspirin 81 mg
• Active Comparator: Oral Daily Aspirin 325 mg

Primary Outcome Measure

Number of patients with new stroke event (ischemic stroke or hemorrhagic stroke) [ Time Frame: From randomization up to 3 months after discharge ]

Central Contacts

• Maryam B Tabrizi, M.D
  (909) 558-4286
  [email protected]
• Sina Asaadi, M.D
  (412) 539-7088
  [email protected]

Locations (1)

Find similar trials in Loma Linda, CA